Table 3 Incidence of worst NCI-CTCAE hematology grades during and up to 28 days after the end of study treatment (all-treated population)
Placebo + dacarbazine (n = 38) | Bosentan + dacarbazine (n = 38) | |||||||
|---|---|---|---|---|---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
Hemoglobin, n (%) | 26 (68.4) | 2 (5.3) | - | - | 19 (50.0) | 9 (23.7) | 1 (2.6) | 1 (2.6) |
Leukocytes, n (%) | 8 (21.1) | 6 (15.8) | 2 (5.3) | - | 10 (26.3) | 7 (18.4) | 1 (2.6) | - |
Neutrophils, n (%) | 4 (10.5) | 5 (13.2) | 2 (5.3) | 1 (2.6) | 3 (7.9) | 8 (21.1) | 1 (2.6) | - |
Platelets, n (%) | 11 (28.9) | 3 (7.9) | - | - | 10 (26.3) | 3 (7.9) | 2 (5.3) | - |